|
KMID : 1001920120510040199
|
|
Journal of Korean Neurosurgical Society
2012 Volume.51 No. 4 p.199 ~ p.202
|
|
|
The Role of Chemotherapy in Anaplastic Astrocytoma Patients
|
|
Kim Sung-Kwon
Kim Jin-Wook
Kim Yong-Hwy
Kim Tae-Min
Lee Se-Hoon
Park Chul-Kee
|
|
|
Abstract
|
|
|
Objective: This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA).
Methods: We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total of 86 patients (39 men and 47 women) with newly diagnosed AA after surgery were analyzed. Among them, 31 patients (36.0%) were treated with radiotherapy only (RT Group), 30 patients (34.9%) were treated with nimustine-cisplatin chemotherapy before RT (ACNU-CDDP group), and 25 patients (29.1%) were treated with procarbazine, lomustine and vincristine (PCV) chemotherapy after radiotherapy (PCV group).
Results: The median survival was 14.0, 30.0 and 72.0 months in RT, ACNU-CDDP, and PCV group, respectively and showed significant differences (RT vs. ACNU-CDDP; p=0.039, RT vs. PCV; 0.002, ACNU-CDDP vs. PCV; 0.045). PCV group showed less toxicity rate (5 patients; 20%) than ACNU-CDDP group (12 patients; 40%), while only 3 patients (9.6%) in RT group experienced grade 3 or 4 toxicities.
Conclusion: An application of chemotherapy before or after radiotherapy is beneficial in prolonging the survival of patients with AA. Adjuvant PCV chemotherapy after radiotherapy is recommendable.
|
|
|
KEYWORD
|
|
|
Anaplastic astrocytoma, Chemotherapy, Procarbazine, Lomustine, Vincristine, PCV, Nimustine-cisplatin
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|